A Smart Europium-Ruthenium Complex as Anticancer Prodrug: Controllable Drug Release and Real-Time Monitoring under Different Light Excitations

Hongguang Li, Chen Xie, Rongfeng Lan, Shuai Zha, Chi Fai Chan, Wing Yan Wong, Ka Lok Ho, Brandon Dow Chan, Yuxia Luo, Jing Xiang Zhang, Ga Lai Law*, William C S TAI, Jean Claude G. Bünzli, Ka-Leung WONG

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)

Abstract

A unique, dual-function, photoactivatable anticancer prodrug, RuEuL, has been tailored that features a ruthenium(II) complex linked to a cyclen-europium chelate via a π-conjugated bridge. Under irradiation at 488 nm, the dark-inactive prodrug undergoes photodissociation, releasing the DNA-damaging ruthenium species. Under evaluation-window irradiation (λirr = one-photon 350 nm or two-photon 700 nm), the drug delivery process can be quantitatively monitored in real-time because of the long-lived red europium emission. Linear relationships between released drug concentration and ESI-MS or luminescence responses are established. Finally, the efficiency of the new prodrug is demonstrated both in vitro RuEuL anticancer prodrug over some existing ones and open the way for decisive improvements in multipurpose prodrugs.

Original languageEnglish
Pages (from-to)8923-8932
Number of pages10
JournalJournal of Medicinal Chemistry
Volume60
Issue number21
DOIs
Publication statusPublished - 9 Nov 2017

Scopus Subject Areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint

Dive into the research topics of 'A Smart Europium-Ruthenium Complex as Anticancer Prodrug: Controllable Drug Release and Real-Time Monitoring under Different Light Excitations'. Together they form a unique fingerprint.

Cite this